

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: ssspta1201txs

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 17:13:44 ON 04 OCT 2004

10/670,665

=> file reg
COST IN U.S. DOLLARS
FULL ESTIMATED COST

SINCE FILE
ENTRY
0.21

TOTAL
SESSION
0.21

FILE 'REGISTRY' ENTERED AT 17:14:01 ON 04 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 3 OCT 2004 HIGHEST RN 756446-64-7
DICTIONARY FILE UPDATES: 3 OCT 2004 HIGHEST RN 756446-64-7


TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=>
Uploading C:\STNEXP4\QUERIES\10670665.str



chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19
ring nodes :
1 2 3 4 5 6
chain bonds :
1-7 6-10 7-8 7-9 10-11 11-12 12-13 13-14 14-15 15-16 16-17 16-18 18-19
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
16-17 16-18
exact bonds :
1-7 6-10 7-8 7-9 10-11 11-12 12-13 13-14 14-15 15-16 18-19
normalized bonds :
1-2 1-6 2-3 3-4 4-5 5-6

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS
19:CLASS

10/670,665

L1 STRUCTURE UPLOADED

=> s 11
SAMPLE SEARCH INITIATED 17:14:17 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 0 TO ITERATE

100.0% PROCESSED 0 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 0 TO 0
PROJECTED ANSWERS: 0 TO 0



L2 0 SEA SSS SAM L1

=> s 11 ful
FULL SEARCH INITIATED 17:14:22 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 4 TO ITERATE

100.0% PROCESSED 4 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

L3 0 SEA SSS FUL L1

=>
Uploading C:\STNEXP4\QUERIES\106706651.str



chain nodes :

7 8 9 10

ring nodes :

1 2 3 4 5 6

chain bonds :

1-7 6-10 7-8 7-9

ring bonds :

1-2 1-6 2-3 3-4 4-5 5-6

exact/norm bonds :

6-10

exact bonds :

1-7 7-8 7-9

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

G1:C,O,N,Cy,Ak

Match level :

10/670,665

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS

L4 STRUCTURE UPLOADED

=> s 14

SAMPLE SEARCH INITIATED 17:17:55 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 2394 TO ITERATE

41.8% PROCESSED 1000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 44946 TO 50814
PROJECTED ANSWERS: 2660 TO 4234

L5 50 SEA SSS SAM L4

=> s 14 ful
FULL SEARCH INITIATED 17:18:02 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 47267 TO ITERATE

100.0% PROCESSED 47267 ITERATIONS 3775 ANSWERS
SEARCH TIME: 00.00.01

L6 3775 SEA SSS FUL L4

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 312.94 313.15

FILE 'CAPLUS' ENTERED AT 17:18:10 ON 04 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 4 Oct 2004 VOL 141 ISS 15
FILE LAST UPDATED: 3 Oct 2004 (20041003/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

10/670,665

=> s 16

L7 1177 L6

=> s 17 and store operated calcium influx

15294 STORE

22395 STORES

35680 STORE

(STORE OR STORES)

83986 OPERATED

696838 CALCIUM

32 CALCIUMS

696841 CALCIUM

(CALCIUM OR CALCIUMS)

39759 INFUX

1063 INFUXES

40283 INFUX

(INFUX OR INFUXES)

45 STORE OPERATED CALCIUM INFUX

(STORE(W) OPERATED(W) CALCIUM(W) INFUX)

L8 0 L7 AND STORE OPERATED CALCIUM INFUX

=> s 17 and calcium

696838 CALCIUM

32 CALCIUMS

696841 CALCIUM

(CALCIUM OR CALCIUMS)

L9 108 L7 AND CALCIUM

=> s 19 and inhibitor

453162 INHIBITOR

471777 INHIBITORS

728228 INHIBITOR

(INHIBITOR OR INHIBITORS)

L10 94 L9 AND INHIBITOR

=> s 110 and SOC

20692 SOC

990 SOCS

21580 SOC

(SOC OR SOCS)

L11 1 L10 AND SOC

=> s 110 and blocking

92971 BLOCKING

30 BLOCKINGS

92990 BLOCKING

(BLOCKING OR BLOCKINGS)

L12 1 L10 AND BLOCKING

=> s 110 and block

202452 BLOCK

78100 BLOCKS

258816 BLOCK

(BLOCK OR BLOCKS)

L13 2 L10 AND BLOCK

=> s 110 and disease

710593 DISEASE

196723 DISEASES

802693 DISEASE

(DISEASE OR DISEASES)

L14 61 L10 AND DISEASE

=> s l10 and inflamat?

185309 INFLAMMAT?

L15 20 L10 AND INFLAMMAT?

=> dup rem l11 l12 l13 l15

PROCESSING COMPLETED FOR L11

PROCESSING COMPLETED FOR L12

PROCESSING COMPLETED FOR L13

PROCESSING COMPLETED FOR L15

L16 21 DUP REM L11 L12 L13 L15 (3 DUPLICATES REMOVED)

=> d l16 ibib hitstr abs 1-21

L16 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 1

ACCESSION NUMBER: 2004:291973 CAPLUS

DOCUMENT NUMBER: 140:309456

TITLE: Perivasicular wraps based on biodegradable polymers containing therapeutic agents

INVENTOR(S): Gravett, David M.; Toleikis, Philip M.; Guan, Dechi; Signore, Pierre E.; Spencer, Thomas S.; Hunter, William L.; Wang, Kaiyue

PATENT ASSIGNEE(S): Angiotech Pharmaceuticals, Inc., Can.

SOURCE: PCT Int. Appl., 92 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004028583	A2	20040408	WO 2003-US30280	20030926
WO 2004028583	A3	20040819		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004146546	A1	20040729	US 2003-673046	20030926
PRIORITY APPLN. INFO.:			US 2002-414714P	P 20020926
			US 2002-414693P	P 20020927

IT 145599-86-6, Cerivastatin


RL: DEV (Device component use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(perivasicular wraps made of biodegradable polymer mesh containing therapeutic agents for prevention or reduction of proliferative biol. response of passageway or cavity after surgery)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



AB The present invention provides compns., devices, and methods for maintaining or improving the integrity of body passageways following surgery, such as at a graft site, or injury. Delivery devices including one or more therapeutic agents and a mesh are described. Representative examples of therapeutic agents include microtubule stabilizing agents, anti-angiogenic factors, **inhibitors** of smooth muscle cell growth or proliferation, non-steroidal anti-inflammatory drugs, and other factors useful in preventing and/or reducing a proliferative biol. response that may obstruct or hinder the optimal functioning of the passageway or cavity. For example, perivascular delivery of paclitaxel from mPEG-DL-lactide copolymer-coated PLGA mesh resulted in a dramatic reduction of intimal hyperplasia in a rat balloon injury carotid artery model.

L16 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:100986 CAPLUS
 DOCUMENT NUMBER: 140:157460
 TITLE: PPAR α -selective chromane and chromene compounds for the treatment of dyslipidemia and other lipid disorders, and preparation thereof
 INVENTOR(S): Desai, Ranjit C.; Sahoo, Soumya
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 57 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004010992	A1	20040205	WO 2003-US23499	20030725
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 2002-399518P	P 20020730
OTHER SOURCE(S):			MARPAT 140:157460	

IT 143201-11-0, Rivastatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)


(PPAR α -selective chromane and chromene compds. for treatment of lipid disorders, preparation, and use with other agents)

RN 143201-11-0 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)-(9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



● Na

GI



AB A class of chromane and chromene compds.. I [R₁, R₂, R₄ = (un)substituted C1-3 alkyl; R₃, R₅, R₇ = H, (un)substituted C1-3 alkyl; R₆ = H, Cl, Me, CF₃; A, B = H, Cl, F, Me, CF₃; X, Y = O, S; n = 2, 3; dashed line = optional double bond], and pharmaceutically acceptable salts thereof, are useful as therapeutic compds., particularly in the treatment and control of hyperlipidemia, hypercholesterolemia, dyslipidemia, and other lipid disorders, and in delaying the onset of or reducing the risk of conditions and sequelae that are associated with these diseases, such as atherosclerosis. Compound preparation is included.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:80450 CAPLUS


DOCUMENT NUMBER: 140:145835


TITLE: Preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as modulators of the glucocorticoid receptor
 INVENTOR(S): Vaccaro, Wayne; Yang, Bingwei Vera; Kim, Soong-hoon; Huynh, Tram; Tortolani, David R.; Leavitt, Kenneth J.; Li, Wenyi; Doweyko, Arthur M.; Chen, Xiao-tao; Doweyko, Lidia
 PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA; et al.
 SOURCE: PCT Int. Appl., 265 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004009017	A2	20040129	WO 2003-US22300	20030717
WO 2004009017	A3	20040708		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004132758	A1	20040708	US 2003-621909	20030717
PRIORITY APPLN. INFO.: MARPAT 140:145835 OTHER SOURCE(S): IT 145599-86-6, Cerivastatin RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (combination pharmaceutical; preparation of dibenzofused bicyclo[2.2.2]octane-derived amides as modulators of glucocorticoid receptor)				
RN	145599-86-6	CAPLUS		
CN	6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E) - (9CI) (CA INDEX NAME)			

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.





AB Title compds. I [R-R4 = H, alk(en/yn)yl, alkoxy, aryl, etc.; Z = carboxamido, alkylamino, etc.] are prepared For instance, 2-amino-4,5-dimethylthiazole is coupled to the acid derived from the cycloaddn. of methacrylic acid and anthracene (CH3CN, EDCI, Et3N, HOAt, 18 h) to give II. I are glucocorticoid receptor modulators which are useful in treating diseases requiring glucocorticoid receptor agonist or antagonist therapy such as obesity, diabetes, **inflammatory** and immune disorders.

L16 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:60341 CAPLUS
 DOCUMENT NUMBER: 140:117406
 TITLE: Liquid dosage compositions of stable nanoparticulate drugs
 INVENTOR(S): Bosch, William H.; Hilborn, Matthew R.; Hovey, Douglas C.; Kline, Laura J.; Lee, Robert W.; Pruitt, John D.; Ryde, Niels P.; Ryde, Tuula A.; Xu, Shuqian
 PATENT ASSIGNEE(S): Elan Pharma International, Ltd, Ire.
 SOURCE: PCT Int. Appl., 68 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 15
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004006959	A1	20040122	WO 2003-US22187	20030716
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			


PRIORITY APPLN. INFO.: US 2002-396530P P 20020716
 IT 145599-86-6, Cerivastatin
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (liquid dosage compns. of stable nanoparticulate drugs)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



AB The present invention relates to liquid dosage compns. of stable nanoparticulate drugs. The liquid dosage compns. of the invention include osmotically active crystal growth **inhibitors** that stabilize the nanoparticulate active agents against crystal and particle size growth of the drug. Thus, an aqueous nanoparticulate colloidal dispersion (NCD) comprising drug 32.5 Copovidone 6.5, and dioctyl sodium sulfosuccinate 0.464% by weight was prepared by milling for 3.8 h under high energy milling conditions. The final mean particle size (by weight) of the drug particles was 161 nm. The concentrated NCD was then diluted with preserved water and glycerol (the osmotically active crystal growth **inhibitor**) to 0.5-3.0% drug.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:41320 CAPLUS

DOCUMENT NUMBER: 140:87743

TITLE: Therapeutic use and pharmaceutical compositions of cholesterol ester transfer protein (CETP) **inhibitors** and optional HMG-CoA reductase **inhibitors** and/or antihypertensive agents

INVENTOR(S): Nguyen, Tu Trung; Shear, Charles Lester; Revkin, James Harold; Ruggeri, Roger Benjamin

PATENT ASSIGNEE(S): Pfizer Products Inc., USA

SOURCE: PCT Int. Appl., 159 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004004778	A1	20040115	WO 2003-IB2792	20030618
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ,				

MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG

US 2004053842 A1 20040318 US 2003-459683 20030610

PRIORITY APPLN. INFO.: US 2002-393395P P 20020702

OTHER SOURCE(S): MARPAT 140:87743

IT 122254-45-9, Glenvastin


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (Glenvastatin; therapeutic use and pharmaceutical compns. of
 cholesterol ester transfer protein **inhibitors** and optional
 HMG-CoA reductase **inhibitors** and/or antihypertensive agents)

RN 122254-45-9 CAPLUS

CN 2H-Pyran-2-one, 6-[(1E)-2-[4-(4-fluorophenyl)-2-(1-methylethyl)-6-phenyl-3-
 pyridinyl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



IT 143201-11-0, Rivastatin 145599-86-6, Cerivastatin


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (therapeutic use and pharmaceutical compns. of cholesterol ester
 transfer protein **inhibitors** and optional HMG-CoA reductase
inhibitors and/or antihypertensive agents)

RN 143201-11-0 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-
 methylethyl)-3-pyridinyl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)-
 (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.




● Na

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
 Double bond geometry as shown.



AB The invention discloses cholesterol ester transfer protein (CETP) **inhibitors**, pharmaceutical compns. containing such **inhibitors**, and the use of such **inhibitors** to treat certain diseases/conditions, optionally in combination with certain therapeutic agents e.g., antihypertensive agents.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2004:451474 CAPLUS

DOCUMENT NUMBER: 141:1258

TITLE: Nitrosated compounds in methods of treating vascular diseases characterized by nitric oxide insufficiency

INVENTOR(S): Loscalzo, Joseph; Vita, Joseph A.; Loberg, Michael D.; Worcel, Manuel

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 23 pp., Cont.-in-part of U.S. Ser. No. 679,257

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 5

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004105850	A1	20040603	US 2003-692724	20031027
US 6635273	B1	20031021	US 2000-697317	20001027
US 2004071766	A1	20040415	US 2003-679257	20031007
PRIORITY APPLN. INFO.:				
			US 1999-162230P	P 19991029
			US 2000-179020P	P 20000131
			US 2000-697317	A1 20001027
			US 2003-679257	A2 20031007

OTHER SOURCE(S): MARPAT 141:1258

IT 145599-86-6D, Cerivastatin, nitrosated compds.


RL: BSU (Biological study, unclassified); PAC (Pharmacological activity);
 THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (nitrosated compds. in methods of treating vascular diseases
 characterized by nitric oxide insufficiency)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



AB The invention provides methods of treating and/or preventing vascular diseases characterized by nitric oxide insufficiency by administering a therapeutically effective amount of at least one nitrosated angiotensin-converting enzyme **inhibitor**, nitrosated beta-adrenergic blocker, nitrosated cholesterol reducer, nitrosated calcium channel blocker, nitrosated endothelin antagonist, nitrosated angiotensin II receptor antagonist, nitrosated renin **inhibitor**, and optionally at least one compound used to treat cardiovascular diseases and/or at least one antioxidant, or a pharmaceutically acceptable salt thereof, and/or at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase. The antioxidant may preferably be a hydralazine compound or a pharmaceutically acceptable salt thereof. The compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase may preferably be isosorbide dinitrate and/or isosorbide mononitrate. The vascular diseases characterized by nitric oxide insufficiency include a cardiovascular disease and a disease resulting from oxidative stress. Nitric oxide action was shown to be impaired in the microvasculature of black hypertensive patients to a greater extent than in white hypertensive patients.

L16 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2004:392331 CAPLUS
 DOCUMENT NUMBER: 140:406798
 TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase **inhibitors**
 INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 44 pp., Cont.-in-part of U.S. Ser. No. 875,155, abandoned.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004092573	A1	20040513	US 2003-602752	20030624
US 2002013334	A1	20020131	US 2001-875155	20010606
PRIORITY APPLN. INFO.:			US 2000-211595P	P 20000615
			US 2001-875155	US 2001-875155
			B2	20010606

OTHER SOURCE(S): MARPAT 140:406798

IT 145599-86-6, Cerivastatin


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase **inhibitors** for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.




IT 380459-94-9P 380459-96-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of benzoxepinopyridines as HMG-CoA reductase **inhibitors** for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

RN 380459-94-9 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




● Na

RN 380459-96-1 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-heptanoic acid, 4-(4-fluorophenyl)-5,6-dihydro-β,δ-dihydroxy-2-(1-methylethyl)-, monosodium salt, (βR,δR)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na


IT 380460-17-3P 380460-19-5P 380460-21-9P
380460-23-1P 380460-25-3P 380460-27-5P
380460-29-7P 380460-31-1P 380460-33-3P
380460-35-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzoxepinopyridines as HMG-CoA reductase **inhibitors** for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)


RN 380460-17-3 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-carboxylic acid, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)





RN 380460-19-5 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-methanol, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)





RN 380460-21-9 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine, 3-(bromomethyl)-4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 380460-23-1 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine, 3-[(diphenylphosphinyl)methyl]-4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 380460-25-3 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 6-[(1E)-2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethenyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 380460-27-5 CAPLUS

CN 2H-Pyran-2-one, 6-[(1E)-2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 380460-29-7 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 6-[2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380460-31-1 CAPLUS


CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethyl]tetrahydro-4-hydroxy-, (4R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380460-33-3 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-carboxaldehyde, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 380460-35-5 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-carboxylic acid, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)-, methyl ester (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, SO, SO₂, NR₇; Z = HOCHCH₂CH(OH)CH₂CO₂R₃, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R₁, R₂ = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R₃ = H, alkyl, metal ion; R₄ = H, halo, CF₃, etc.; R₇ = H, alkyl, aryl,

alkanoyl, aroyl, alkoxycarbonyl, etc.; R9, R10 = H, alkyl], were prepared as HMG CoA reductase **inhibitors** active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis (no data). A multistep synthesis of II is reported.

L16 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:913055 CAPLUS

DOCUMENT NUMBER: 139:399770

TITLE: Medical goods comprising heparin or chitosan-based hemocompatible coating

INVENTOR(S): Horres, Roland; Linssen, Marita Katharina; Hoffmann, Michael; Faust, Volker; Hoffmann, Erika; Di Biase, Donato

PATENT ASSIGNEE(S): Hemotec G.m.b.H., Germany

SOURCE: PCT Int. Appl., 93 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003094990	A1	20031120	WO 2003-DE1253	20030415
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10221055	A1	20031127	DE 2002-10221055	20020510
DE 10261986	A1	20040318	DE 2002-10261986	20020510
PRIORITY APPLN. INFO.:			US 2002-378676P	P 20020509
			DE 2002-10221055	A 20020510

IT 145599-86-6, Cerivastatin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(medical goods comprising a heparin-based hemocompatible coating)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



AB The invention relates to oligo- and polysaccharides containing the sugar structural element N-acetylgalactosamine or N-acetylgalactosamine, in addition to the use thereof for producing hemocompatible surfaces and to methods for coating surfaces in a hemocompatible manner with said oligo- and polysaccharides, which constitute the common biosynthetic precursor substances of heparin, heparan sulfates and chitosan. The invention also relates to methods for producing the oligo- and/or polysaccharides, in addition to diverse application options involving hemocompatible surfaces. The invention specifically relates to the use of the oligo- and/or polysaccharides on stents involving at least one hemocompatible coating that has been applied according to the invention and that contains an anti-proliferative, anti-inflammatory and/or athrombogenic active ingredient, to methods for producing said stents and to the use of the latter for preventing restenosis. Thus desulfated and reacetylated heparin was prepared; the Ac-heparin product was used for coating coronary metal stents. The stents were implanted in swines; after four weeks the animals were anesthetized and the artery segments removed for histomorphometric anal.

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:892539 CAPLUS

DOCUMENT NUMBER: 139:375605

TITLE: Synthesis and uses of 4-azasteroid derivatives as selective androgen receptor modulators (SARMs)

INVENTOR(S): Wang, Jiabing; McVean, Carol A.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 181 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003092588	A2	20031113	WO 2003-US13120	20030425
WO 2003092588	A3	20040715		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,				

CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG

PRIORITY APPLN. INFO.: US 2002-376779P P 20020430

OTHER SOURCE(S): MARPAT 139:375605

IT 145599-86-6, Cerivastatin


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)
(in addition to SARMs treatment; synthesis and uses of 4-azasteroid
derivs. as selective androgen receptor modulators (SARMs) in the
treatment of androgen deficiency-related diseases)

RN 145599-86-6 CAPLUS


CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



GI



AB Compds. of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. These compds. are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other

hematopoietic disorders, inflammatory arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, Alzheimer's disease, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

L16 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2003:757525 CAPLUS

DOCUMENT NUMBER: 139:277056

TITLE: Preparation of fluorinated 4-aza-androstan-3-one-17 β -carboxamide derivatives as androgen receptor modulators

INVENTOR(S): Meissner, Robert S.; Perkins, James J.

PATENT ASSIGNEE(S): Merck & Co., Inc., USA

SOURCE: PCT Int. Appl., 95 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003077919	A1	20030925	WO 2003-US8277	20030307
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				

PRIORITY APPLN. INFO.: US 2002-363822P P 20020313

OTHER SOURCE(S): MARPAT 139:277056

IT 145599-86-6, Cerivastatin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(bone strengthening agents as adjuvant therapeutics; preparation of fluorinated 4-aza-androstan-3-one-17 β -carboxamide derivs. as androgen receptor modulators and their therapeutic uses)


RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.





AB Fluorinated 4-aza-androstan-3-one-17 β -carboxamide derivs., such as I [a-b = CF:CH, CHFCH2, CF2CH2; R1 = H, CH2OH, (un)substituted alkyl; R2 = H, alkyl; R3 = alkyl, cycloheteroalkyl, aryl, heteroaryl; R2R3 = 5 or 6-membered ring fused with a 5- or 6-membered aromatic ring system having 0-2 heteroatoms], or a pharmaceutically acceptable salt or an enantiomer thereof, were prepared for their use as modulators of the androgen receptor (AR) in a tissue selective manner. Thus, 4-aza-androstan-3-one-17 β -carboxamide derivative II, was prepared via a multiple step reaction sequence starting from 4-methyl-4-aza-androstan-3-one-17-carboxylic acid Me ester and 2-fluoro-benzylamine. The prepared compds. are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a male patient or in the uterus of a female patient. I are therefore useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteoporosis, osteopenia, glucocorticoid-induced osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, obesity, aplastic anemia and other hematopoietic disorders, **inflammatory** arthritis and joint repair, HIV-wasting, prostate cancer, cancer cachexia, muscular dystrophies, premature ovarian failure, and autoimmune disease, alone or in combination with other active agents.

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
 ACCESSION NUMBER: 2003:377132 CAPLUS
 DOCUMENT NUMBER: 138:367144
 TITLE: Soluble CD40L (CD154) as a prognostic marker of atherosclerotic diseases
 INVENTOR(S): Schoenbeck, Uwe; Ridker, Paul M.; Libby, Peter
 PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA
 SOURCE: PCT Int. Appl., 66 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003040691	A2	20030515	WO 2002-US35505	20021105
WO 2003040691	A3	20031113		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2003152566	A1	20030814	US 2002-288253	20021105
EP 1451577	A2	20040901	EP 2002-780578	20021105
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			US 2001-338841P	P 20011105
			WO 2002-US35505	W 20021105


IT 145599-86-6, Cerivastatin

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(soluble CD40L as prognostic marker of atherosclerotic diseases, and use in therapeutic agent assessment)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



AB The invention involves the new use of a diagnostic test to determine the risk of atherosclerotic diseases, e.g. myocardial infarction and stroke, particularly among individuals with no signs or symptoms of current disease and among nonsmokers. Further, the invention involves the new use of a diagnostic test to assist physicians in determining which individuals at risk will preferentially benefit from certain treatments designed either to prevent first or recurrent myocardial infarctions and strokes, or to treat acute and chronic cardiovascular disorders. Methods for treatment are also described.

DOCUMENT NUMBER: 138:281598
 TITLE: Androstane compounds as androgen receptor (AR) modulators for the treatment of AR-related diseases
 INVENTOR(S): Wang, Jiabing
 PATENT ASSIGNEE(S): Merck & Co., Inc., USA
 SOURCE: PCT Int. Appl., 83 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003026568	A2	20030403	WO 2002-US29436	20020917
WO 2003026568	A3	20040226		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1429779	A2	20040623	EP 2002-766288	20020917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
PRIORITY APPLN. INFO.:			US 2001-324124P	P 20010921
			WO 2002-US29436	W 20020917


OTHER SOURCE(S): MARPAT 138:281598

IT 145599-86-6, Cerivastatin
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (androstane compds. as androgen receptor (AR) modulators in conjunction with bone-strengthening agents for treatment of AR-related diseases)
 RN 145599-86-6 CAPLUS
 CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.





AB Compds. of structural formula (I) as herein defined are claimed as useful in a method for modulating a function of the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of activating the function of the androgen receptor in a patient, and in particular the method wherein the function of the androgen receptor is blocked in the prostate of a male patient or in the uterus of a female patient and activated in bone and/or muscle tissue. These compds. are useful in the treatment of conditions caused by androgen deficiency or which can be ameliorated by androgen administration, including osteopenia, osteoporosis, periodontal disease, bone fracture, bone damage following bone reconstructive surgery, sarcopenia, frailty, aging skin, male hypogonadism, female sexual dysfunction, postmenopausal symptoms in women, atherosclerosis, hypercholesterolemia, hyperlipidemia, aplastic anemia and other hematopoietic disorders, pancreatic cancer, renal cancer, prostate cancer, **inflammatory** arthritis and joint repair, alone or in combination with other active agents. Methods for the co-administration of those compds. with bone-strengthening agents are also claimed.

L16 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:927184 CAPLUS

DOCUMENT NUMBER: 138:14048

TITLE: Preparation of oxazolylethoxyphenylprolines and related compounds as antidiabetic and antiobesity agents.

INVENTOR(S): Cheng, Peter T.; Jeon, Yoon; Wang, Wei

PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002096357	A2	20021205	WO 2002-US16628	20020523
WO 2002096357	A3	20030925		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,				

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
 PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
 UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU,
 TJ, TM

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
 BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

US 2003092697 A1 20030515 US 2002-153342 20020522

EP 1401433 A2 20040331 EP 2002-737192 20020523

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

PRIORITY APPLN. INFO.: US 2001-294505P P 20010530
 WO 2002-US16628 W 20020523

OTHER SOURCE(S): MARPAT 138:14048

IT 145599-86-6, Cerivastatin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (coadministration; preparation of oxazolylethoxyphenylprolines and related
 compds. as antidiabetic and antiobesity agents)

RN 145599-86-6 CAPLUS


CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-
 methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry. Rotation (+).


Double bond geometry as shown.



GI



I



II

AB Title compds. [I; m, n = 0-2; Q = C, N; A = $(CH_2)_x$, $(CH_2)_{x1}$, with an alkenyl or alkynyl bond in the chain, $(CH_2)_{x2}O(CH_2)_{x3}$; x = 1-5; $x1 = 2-5$; $x2, x3 = 0-5$; provided that ≥ 1 of $x2$ and $x3 \neq 0$; X1 = CH, N; X2 = C, N, O, S; X3 = C, N; X4 = C, N, O, S provided that ≥ 1 of X2, X3, X4 = N; in each of X1-X4, C may include CH; R1 = H, alkyl; R2 = H, alkyl, alkoxy, halo, (substituted) amino; R2a, R2b, R2c = H, alkyl, alkoxy, halo, (substituted) amino; R3 = H, alkyl, arylalkyl, aryloxycarbonyl, alkyloxycarbonyl, alkynyloxycarbonyl, alkenyloxycarbonyl, arylcarbonyl, alkylcarbonyl, aryl, heteroaryl, cycloheteroalkyl, heteroarylcarbonyl, heteroarylheteroarylalkyl, alkylcarbonylamino, arylcarbonylamino, heteroarylcarbonylamino, alkoxy carbonylamino, aryloxycarbonylamino, heteroaryloxycarbonylamino, heteroaryl heteroarylcarbonyl, alkylsulfonyl, alkenylsulfonyl, heteroaryloxycarbonyl, cycloheteroalkyloxycarbonyl, aryloxyheteroarylalkyl, heteroarylalkyloxylalkyl, arylarylalkyl, arylalkenylarylalkyl, arylaminoarylalkyl, etc.; Y = CO2R4, 1-tetrazolyl, P(O)(OR4a)R5, P(O)(OR4a)2; R4 = H, alkyl, prodrug ester; R4a = H, prodrug ester; R5 = alkyl, aryl; Z = $(CH_2)_{x4}$, $(CH_2)_{x5}$, $(CH_2)_{x6}O(CH_2)_{x7}$; x4 = 1-5; x5 = 2-5; x6, x7 = 0-4], were prepared as antidiabetic and antiobesity agents (no data). Thus, title compound (II) was prepared in 6 steps.

L16 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:540258 CAPLUS
 DOCUMENT NUMBER: 137:109267
 TITLE: Preparation of benzoxepinopyridines as HMG-CoA reductase inhibitors
 INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-chi; Sun, Chong-qing
 USA
 PATENT ASSIGNEE(S):
 SOURCE: U.S. Pat. Appl. Publ., 42 pp., Cont.-in-part of U.S. Ser. No. 875,155.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002094977	A1	20020718	US 2001-7407	20011204
US 6627636	B2	20030930		

US 2002013334	A1	20020131	US 2001-875155	20010606
PRIORITY APPLN. INFO.:			US 2000-211595P	P 20000615
			US 2001-875155	A2 20010606

OTHER SOURCE(S): MARPAT 137:109267

IT 145599-86-6, Cerivastatin


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(coadministered agents; preparation of benzoxepinopyridines as HMG-CoA reductase **inhibitors** for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



IT 380459-94-9P 380459-96-1P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of benzoxepinopyridines as HMG-CoA reductase **inhibitors** for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

RN 380459-94-9 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




● Na

RN 380459-96-1 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-heptanoic acid, 4-(4-fluorophenyl)-5,6-dihydro-β,δ-dihydroxy-2-(1-methylethyl)-, monosodium salt, (βR,δR) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● Na

IT 380460-17-3P 380460-19-5P 380460-21-9P

380460-23-1P 380460-25-3P 380460-27-5P

380460-29-7P 380460-31-1P 380460-33-3P


380460-35-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of benzoxepinopyridines as HMG-CoA reductase **inhibitors** for treatment of hyperlipidemia, hypercholesterolemia, hypertriglyceridemia, atherosclerosis, and other disorders)

RN 380460-17-3 CAPLUS



CN [1]Benzoxepino[5,4-b]pyridine-3-carboxylic acid, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)





RN 380460-19-5 CAPLUS
CN [1]Benzoxepino[5,4-b]pyridine-3-methanol, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 380460-21-9 CAPLUS
CN [1]Benzoxepino[5,4-b]pyridine, 3-(bromomethyl)-4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 380460-23-1 CAPLUS
CN [1]Benzoxepino[5,4-b]pyridine, 3-[(diphenylphosphinyl)methyl]-4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)




RN 380460-25-3 CAPLUS

1,3-Dioxane-4-acetic acid, 6-[(1E)-2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethenyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 380460-27-5 CAPLUS

CN 2H-Pyran-2-one, 6-[(1E)-2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


Double bond geometry as shown.



RN 380460-29-7 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 6-[2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380460-31-1 CAPLUS


CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)[1]benzoxepino[5,4-b]pyridin-3-yl]ethyl]tetrahydro-4-hydroxy-, (4R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 380460-33-3 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-carboxaldehyde, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 380460-35-5 CAPLUS

CN [1]Benzoxepino[5,4-b]pyridine-3-carboxylic acid, 4-(4-fluorophenyl)-5,6-dihydro-2-(1-methylethyl)-, methyl ester (9CI) (CA INDEX NAME)



GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [X = O, S, SO, SO₂, NR₇; Z = HOCHCH₂CH(OH)CH₂CO₂R₃, 4-hydroxy-2-oxopyran-6-yl, etc.; n = 0, 1; R₁, R₂ = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R₃ = H, alkyl, metal ion; R₄ = H, halo, CF₃, etc.; R₇ = H, alkyl, aryl,

alkanoyl, aroyl, alkoxy carbonyl, etc.; R9, R10 = H, alkyl], were prepared as HMG CoA reductase inhibitors active in inhibiting cholesterol biosynthesis, modulating blood serum lipids such as lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis (no data). A multistep synthesis of II is reported.

L16 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2002:392237 CAPLUS

DOCUMENT NUMBER: 136:401651

TITLE: Preparation of fused pyridine derivatives as HMG-CoA reductase inhibitors

INVENTOR(S): Robl, Jeffrey A.; Chen, Bang-Chi; Sun, Chong-Qing

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 46 pp., Cont.-in-part of U.S. Ser. No. 875,218.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2002061901	A1	20020523	US 2001-8154	20011204
US 6620821	B2	20030916		
US 2002028826	A1	20020307	US 2001-875218	20010606
US 2004024216	A1	20040205	US 2003-602753	20030624
PRIORITY APPLN. INFO.:			US 2000-211594P	P 20000615
			US 2001-875218	A2 20010606
			US 2001-8154	A3 20011204

OTHER SOURCE(S): MARPAT 136:401651

IT 380469-07-8P 380469-08-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(preparation of fused pyridine derivs. as HMG-CoA reductase inhibitors)

RN 380469-07-8 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 380469-08-9 CAPLUS


10/670,665

CN L-Arginine, mono[(3R,5S,6E)-7-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]-3,5-dihydroxy-6-heptenoate] (9CI) (CA INDEX NAME)

CM 1

CRN 380469-07-8
CMF C30 H32 F N O4


Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 74-79-3
CMF C6 H14 N4 O2

Absolute stereochemistry.



IT 380468-71-3P 380468-73-5P 428863-94-9P
428876-96-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of fused pyridine derivs. as HMG-CoA reductase inhibitors)

RN 380468-71-3 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]-3,5-dihydroxy-, monosodium salt, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.




● Na

RN 380468-73-5 CAPLUS

CN 5H-Benzocyclohepta[1,2-b]pyridine-3-heptanoic acid,
4-(4-fluorophenyl)-6,7-dihydro- β , δ -dihydroxy-2-(1-methylethyl)-
, monosodium salt, (β R, δ R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● Na

RN 428863-94-9 CAPLUS

CN 5H-Benzocyclohepta[1,2-b]pyridine-3-heptanoic acid,
4-(4-fluorophenyl)-6,7-dihydro- β , δ -dihydroxy-2-(1-methylethyl)-
, (β R, δ R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 428876-96-4 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]-3,5-dihydroxy-, calcium salt (2:1), (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



●1/2 Ca

IT 135427-12-2P 135454-77-2P 137586-44-8P

380464-21-1P 380468-91-7P 380468-93-9P

380468-95-1P 380468-97-3P 380468-99-5P


380469-01-2P 380469-05-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)


(preparation of fused pyridine derivs. as HMG-CoA reductase inhibitors)

RN 135427-12-2 CAPLUS


CN 5H-Benzocyclohepta[1,2-b]pyridine-3-carboxaldehyde, 4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)





RN 135454-77-2 CAPLUS
CN 5H-Benzocyclohepta[1,2-b]pyridine-3-methanol, 4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 137586-44-8 CAPLUS
CN 5H-Benzocyclohepta[1,2-b]pyridine-3-carboxylic acid, 4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-, ethyl ester (9CI) (CA INDEX NAME)




RN 380464-21-1 CAPLUS
CN 5H-Benzocyclohepta[1,2-b]pyridine, 3-(bromomethyl)-4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 380468-91-7 CAPLUS

CN Phosphonic acid, [4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]methyl-, diethyl ester (9CI) (CA INDEX NAME)




RN 380468-93-9 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 6-[(1E)-2-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]ethenyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.



RN 380468-95-1 CAPLUS


CN 2H-Pyran-2-one, 6-[(1E)-2-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-

10/670,665

methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]ethenyl]tetrahydro-4-hydroxy-, (4R,6S)- (9CI) (CA INDEX NAME)



Absolute stereochemistry.

Double bond geometry as shown.



RN 380468-97-3 CAPLUS


CN 5H-Benzo[6,7]cyclohepta[1,2-b]pyridine, 3-[(diphenylphosphinyl)methyl]-4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)- (9CI) (CA INDEX NAME)



RN 380468-99-5 CAPLUS

CN 1,3-Dioxane-4-acetic acid, 6-[2-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]ethyl]-2,2-dimethyl-, 1,1-dimethylethyl ester, (4R,6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 380469-01-2 CAPLUS


CN 2H-Pyran-2-one, 6-[2-[4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-5H-benzo[6,7]cyclohepta[1,2-b]pyridin-3-yl]ethyl]tetrahydro-4-hydroxy-, (4R,6R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 380469-05-6 CAPLUS

CN 5H-Benzo[6,7]cyclohepta[1,2-b]pyridine-3-acetic acid, 4-(4-fluorophenyl)-6,7-dihydro-2-(1-methylethyl)-, methyl ester (9CI) (CA INDEX NAME)



IT 145599-86-6, Cerivastatin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(therapeutic compns. also containing; preparation of fused pyridine derivs.

as
HMG-CoA reductase **inhibitors**)


RN 145599-86-6 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



GI




AB The title compds. I and their pharmaceutically acceptable salts, esters, prodrug esters, and stereoisomers are claimed [wherein: Z = CH(OH)CH₂CR₇(OH)CH₂CO₂R₃ or corresponding pyranone lactone derivs.; n = 0, 1; x = 0, 1, 2, 3, or 4; y = 0, 1, 2, 3 or 4, provided that at least one of x and y is other than 0; and optionally one or more carbons of (CH₂)_x and/or (CH₂)_y together with addnl. carbons form a 3 to 7 membered spirocyclic ring; R₁, R₂ = alkyl, arylalkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, heteroaryl, cycloheteroalkyl; R₃ = H or lower alkyl; R₄ = H, halo, CF₃, OH, alkyl, alkoxy, CO₂H, (un)substituted NH₂, cyano, (un)substituted CONH₂, etc.; R₇ = H, alkyl]. The compds. are HMG-CoA reductase **inhibitors**, and are active in inhibiting cholesterol biosynthesis and modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol (no data). I are thus useful in treating hyperlipidemia and dyslipidemia, in hormone replacement therapy, and in treating hypercholesterolemia, hypertriglyceridemia and atherosclerosis, as well as Alzheimer's disease and osteoporosis. Preps. of several compds. are described. For instance, a multistep synthesis of fused pyridine derivative II is reported. Compds. I may be used in a manner

similar to atorvastatin, pravastatin, simvastatin, etc. Combinations of compds. I with various other drugs are claimed, the latter being specified as certain pharmacol. classes, as **inhibitors** of specific enzymes, as (ant)agonists of specific receptors, and as numerous named drugs.

L16 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN
ACCESSION NUMBER: 2003:51509 CAPLUS
DOCUMENT NUMBER: 139:159743
TITLE: Cerivastatin potentiates nitric oxide release and eNOS expression through inhibition of isoprenoids synthesis
AUTHOR(S): Kalinowski, L.; Dobrucki, I. T.; Malinski, T.
CORPORATE SOURCE: Department of Laboratory Medicine, Laboratory of Cellular and Molecular Nephrology, Medical Research Center of the Polish Academy of Science, Medical University of Gdansk, Gdansk, Pol.
SOURCE: Journal of Physiology and Pharmacology (2002), 53(4, Pt. 1), 585-595
CODEN: JPHPEI; ISSN: 0867-5910
PUBLISHER: Polish Physiological Society
DOCUMENT TYPE: Journal
LANGUAGE: English
IT 145599-86-6, Cerivastatin
RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cerivastatin potentiates nitric oxide release and eNOS expression through inhibition of isoprenoids synthesis)
RN 145599-86-6 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



AB Endothelium dysfunction, which is often defined as a decrease in NO bioavailability, is one of the earliest manifestations of endothelium-impaired function disorders, including atherosclerosis. Although improvement in NO bioavailability has been attributed to the lowering of serum cholesterol levels, recent studies suggest that HMG-CoA reductase **inhibitors**, statins, may have direct effects on NO bioavailability by little known mechanisms that are independent of serum cholesterol levels. The long-term effect of cerivastatin on NO release from endothelial cells was determined by using highly sensitive electrochem. microsensors and was correlated with endothelial NO synthase (eNOS) levels. To explore whether changes in isoprenoid synthesis affect NO bioavailability and eNOS expression, human endothelial cells were treated with cerivastatin, L-mevalonate (MVA; 1.5 mmol/L),

geranylgeranylpyrophosphate (GGPP; 1 mg/mL) and farnesylpyrophosphate (FPP; 1 mg/mL). Cerivastatin increased spontaneous (by 53% \pm 6) and an eNOS-stimulated NO release (by 41 \pm 6% for calcium ionophore and by 47 \pm 5% acetylcholine) as well as eNOS expression (by 118 \pm 6%) in the same concentration-range. Cerivastatin-dependent increase in both NO release and eNOS expression was revealed after apprx.4 h of exposure reaching the maximum after apprx.10 h. Co-treatment with MVA or GGPP, but not FPP or LDL, reversed the effects of cerivastatin. These findings indicate that the long-term effect of cerivastatin resulting in enhanced NO bioavailability in endothelial cell is, at least in part, due to up-regulation of eNOS by blocking isoprenoids synthesis.

REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 2

ACCESSION NUMBER: 2001:338762 CAPLUS

DOCUMENT NUMBER: 134:362292

TITLE: Methods of determining individual hypersensitivity to a pharmaceutical agent from gene expression profile

INVENTOR(S): Farr, Spencer

PATENT ASSIGNEE(S): Phase-1 Molecular Toxicology, USA

SOURCE: PCT Int. Appl., 222 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001032928	A2	20010510	WO 2000-US30474	20001103
WO 2001032928	A3	20020725		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			US 1999-165398P	P 19991105
			US 2000-196571P	P 20000411

IT 145599-86-6, Cerivastatin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)

(methods of determining individual hypersensitivity to a pharmaceutical agent


from gene expression profile)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



AB The invention discloses methods, gene databases, gene arrays, protein arrays, and devices that may be used to determine the hypersensitivity of individuals to a given agent, such as drug or other chemical, in order to prevent toxic side effects. In one embodiment, methods of identifying hypersensitivity in a subject by obtaining a gene expression profile of multiple genes associated with hypersensitivity of the subject suspected to be hypersensitive, and identifying in the gene expression profile of the subject a pattern of gene expression of the genes associated with hypersensitivity are disclosed. The gene expression profile of the subject may be compared with the gene expression profile of a normal individual and a hypersensitive individual. The gene expression profile of the subject that is obtained may comprise a profile of levels of mRNA or cDNA. The gene expression profile may be obtained by using an array of nucleic acid probes for the plurality of genes associated with hypersensitivity. The expression of the genes predetd. to be associated with hypersensitivity is directly related to prevention or repair of toxic damage at the tissue, organ or system level. Gene databases arrays and apparatus useful for identifying hypersensitivity in a subject are also disclosed.

L16 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN DUPLICATE 3

ACCESSION NUMBER: 2001:396644 CAPLUS

DOCUMENT NUMBER: 135:24671

TITLE: Solid carriers for improved delivery of active ingredients in pharmaceutical compositions

INVENTOR(S): Patel, Manesh V.; Chen, Feng-jing

PATENT ASSIGNEE(S): Lipocene, Inc., USA

SOURCE: PCT Int. Appl., 107 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 12

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001037808	A1	20010531	WO 2000-US32255	20001122
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6248363	B1	20010619	US 1999-447690	19991123

EP 1233756	A1 20020828	EP 2000-980761	20001122
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
JP 2003517470	T2 20030527	JP 2001-539423	20001122
PRIORITY APPLN. INFO.:		US 1999-447690	A 19991123
		WO 2000-US32255	W 20001122

IT 145599-86-6, Cerivastatin


RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(solid carriers for improved delivery of active ingredients in
pharmaceutical compns.)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.



AB The present invention provides solid pharmaceutical compns. for improved delivery of a wide variety of pharmaceutical active ingredients contained therein or sep. administered. In one embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier including a substrate and an encapsulation coat on the substrate. The encapsulation coat can include different combinations of pharmaceutical active ingredients, hydrophilic surfactant, lipophilic surfactants and triglycerides. In another embodiment, the solid pharmaceutical composition includes a solid carrier, the solid carrier being formed of different combinations of pharmaceutical active ingredients, hydrophilic surfactants, lipophilic surfactants and triglycerides. The compns. of the present invention can be used for improved delivery of hydrophilic or hydrophobic pharmaceutical active ingredients, such as drugs, nutritionals, cosmeceuticals and diagnostic agents. A composition contained glyburide 1, PEG 40 stearate 33, glycerol monolaurate 17, and nonpareil seed 80 g.

REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:661287 CAPLUS

DOCUMENT NUMBER: 135:216008

TITLE: P-glycoprotein modifier-containing medicinal compositions to be delivered to the large intestine

INVENTOR(S): Tanida, Norifumi; Goto, Takeshi; Kurosaki, Yuji

PATENT ASSIGNEE(S): Hisamitsu Pharmaceutical Co., Inc., Japan

SOURCE: PCT Int. Appl., 20 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001064253	A1	20010907	WO 2001-JP1546	20010301
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 2001036009	A5	20010912	AU 2001-36009	20010301
EP 1260233	A1	20021127	EP 2001-908178	20010301
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
US 2003158097	A1	20030821	US 2002-220551	20021121
PRIORITY APPLN. INFO.:			JP 2000-57630	A 20000302
			WO 2001-JP1546	W 20010301

IT 145599-86-6, Cerivastatin

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(P-glycoprotein modifiers for drug delivery to intestine)

RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.

AB Disclosed are novel medicinal compns. aiming at delivering a medicine to a specific site of the large intestine; and preps. for intestinal administration with the use of the same. P-glycoprotein enhancers and **inhibitors** in the compns. allow specific drug delivery in the lower or upper intestine. A tablet was formulated containing betamethasone sodium phosphate 2, verapamil (as P-glycoprotein **inhibitor**) 1, crystalline cellulose 10, lactose 81, crospovidone 5, and Mg stearate 1 part was coated with a coating composition containing Eudragit E 7, ethanol 70, water 19.5, and talc 3.5 parts.

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L16 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:283949 CAPLUS

DOCUMENT NUMBER: 134:311218

TITLE: Synthesis and use of heterocyclic sodium/proton

exchange inhibitors

INVENTOR(S) : Ahmad, Saleem; Wu, Shung C.; O'Neil, Steven V.; Ngu, Khehyong; Atwal, Karnail S.

PATENT ASSIGNEE(S) : Bristol-Myers Squibb Company, USA

SOURCE: PCT Int. Appl., 221 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001027107	A2	20010419	WO 2000-US27461	20001002
WO 2001027107	A3	20020124		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1224183	A2	20020724	EP 2000-968723	20001002
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
BR 2000014725	A	20030617	BR 2000-14725	20001002
JP 2003527331	T2	20030916	JP 2001-530325	20001002
NO 2002001717	A	20020610	NO 2002-1717	20020411
PRIORITY APPLN. INFO.:			US 1999-158755P	P 19991012
			WO 2000-US27461	W 20001002

OTHER SOURCE(S) : MARPAT 134:311218

IT 145599-86-6, Cerivastatin

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)


(pharmaceuticals also containing; synthesis and use of heterocyclic sodium/proton exchange inhibitors)


RN 145599-86-6 CAPLUS

CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E) - (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).

Double bond geometry as shown.





AB Compds. of formula I [wherein; n is 1-5; X is N or CR₅, where R₅ is H, halo, alkenyl, alkynyl, alkoxy, alkyl, aryl or heteroaryl; Z is a heteroaryl group; R₁ is H, alk(en)(yn)yl, alk(enyl)(ynyl)oxy, (aryl or alkyl)3Si, cycloalk(en)yl, (aryl)amino, aryl(alkyl), cycloheteroaryl, etc.; R₂, R₃ and R₄ are any of the groups set out for R₁ and optionally substituted with 1 to 5 substituents which may be the same or different and when X is N, R₁ is preferably aryl or heteroaryl] are claimed. Several hundred examples are disclosed. Synthesis of II proceeds via cyclopropanation of the cinnamate derived from the olefination between 3,5-dichlorobenzaldehyde and t-butylidieethylphosphonoacetate. The intermediate tert-Bu ester is converted to the corresponding α -chloroketone and reacted with acetyl guanidine to provide II in a total of 5 steps. Compds. I are said to be sodium/proton exchange inhibitors (NHE). Pharmaceutical combinations are claimed using I and certain antihypertensive agents, β -adrenergic agonists, hypolipidemic agents, antidiabetic agents, antiobesity agents, etc. Compds. I are useful as antianginal and cardioprotective agents and provide a method for preventing or treating angina pectoris, cardiac dysfunction, myocardial necrosis, and arrhythmia.

L16 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2004 ACS on STN

ACCESSION NUMBER: 2001:167849 CAPLUS
 DOCUMENT NUMBER: 134:217194
 TITLE: Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases
 INVENTOR(S): Ridker, Paul; Hennekens, Charles H.
 PATENT ASSIGNEE(S): The Brigham and Women's Hospital, Inc., USA
 SOURCE: PCT Int. Appl., 53 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001015744	A1	20010308	WO 2000-US24251	20000831
WO 2001015744	C2	20020926		
W: AU, CA, JP				
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
EP 1212101	A1	20020612	EP 2000-959851	20000831
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				

JP 2003508453 T2 20030304 JP 2001-520155 20000831
PRIORITY APPLN. INFO.: US 1999-387028 A 19990831
WO 2000-US24251 W 20000831

IT 145599-86-6, Cerivastatin
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(use of agents and systemic inflammatory markers to predict and inhibit cardiovascular disorders in humans)

RN 145599-86-6 CAPLUS
CN 6-Heptenoic acid, 7-[4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl]-3,5-dihydroxy-, (3R,5S,6E)- (9CI) (CA INDB NAME)

Absolute stereochemistry. Rotation (+).
Double bond geometry as shown.



AB The invention involves methods for characterizing an individual's risk profile of developing a future cardiovascular disorder such as atherosclerosis, stroke, and myocardial infarction by assessing the level of systemic **inflammation** marker (such as sICAM or C-reactive protein) in an individual. The invention also involves methods for evaluating the likelihood that an individual will benefit from treatment with an agent for reducing the risk of future cardiovascular disorders; and of drug combinations (anti-**inflammatory** agents, lipid-reducing agents, angiotensin system **inhibitors**, **calcium** channel blockers, β -adrenergic receptor blockers) suitable for prevention future cardiovascular disease.

REFERENCE COUNT: 13 THERE ARE 13 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y
 COST IN U.S. DOLLARS SINCE FILE TOTAL
 ENTRY SESSION
 FULL ESTIMATED COST 126.14 439.29
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
 ENTRY SESSION
 CA SUBSCRIBER PRICE -14.70 -14.70

STN INTERNATIONAL LOGOFF AT 17:26:23 ON 04 OCT 2004